Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

2seventy bio, Inc. - Common Stock (NQ:TSVT)

4.970 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 2seventy bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting
From 2seventy bio
Via Business Wire
2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program
From 2seventy bio
Via Business Wire
2seventy bio's Return On Capital Employed Overview
Via Benzinga
Wedbush Maintains Outperform Rating for 2seventy bio: Here's What You Need To Know
Via Benzinga
Where 2seventy bio Stands With Analysts
Via Benzinga
SVB Leerink Maintains Outperform Rating for 2seventy bio: Here's What You Need To Know
Via Benzinga
2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023
From 2seventy bio, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 147 stocks made new 52-week lows. 
Via Benzinga
Expert Ratings for 2seventy bio
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday's session, 149 stocks hit new 52-week lows. 
Via Benzinga
Legend Biotech Breaks Out After Leaked Documents Show Big CAR-T Benefit
The company could have the best-in-class CAR-T drug for multiple myeloma patients. 
Via Investor's Business Daily
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors
From 2seventy bio, Inc.
Via Business Wire
2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Pricing of Upsized Public Offering of Common Stock
From 2seventy bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
2seventy bio Announces Proposed Public Offering of Common Stock
From 2seventy bio, Inc.
Via Business Wire
Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients
Via Benzinga
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study
From Bristol Myers Squibb
Via Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Provides Company Outlook for 2023
From 2seventy bio, Inc.
Via Business Wire
2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors
From 2seventy bio, Inc.
Via Business Wire
4 Analysts Have This to Say About 2seventy bio
Over the past 3 months, 4 analysts have published their opinion on 2seventy bio (NASDAQ:TSVT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
From 2seventy bio, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  Thursday's session saw 329 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 298 companies achieved new lows for the year. 
Via Benzinga
2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
From 2seventy bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.